Search ARM

Past Industry Events



BIO-Europe Spring 2013

March 11–13, 2013

ARM Members will receive a $200 discount to the event. To receive the discount, members must write the discount code “ARM member” in the comments field within the online registration form.

Future Direction of Stem Cells in Cardiovascular Disease

March 8, 2013

Due to the popularity of this event, priority seating is available until 5:45 p.m. for pre-registered attendees who arrive by this time. Seating will be available to on-site registrants after 5:45 p.m.

Phacilitate Cell & Gene Therapy Forum 2013

January 28–30, 2013

The preeminent industry-led meeting place pushing the maturation of regulatory, manufacturing, R&D and commercial strategies. Delivering the information and contacts you need to drive your cell and gene therapy products forward. ARM members receive a 10% discount on registration.

Biotech Showcase Regen Med Track

January 8, 2013

In partnership with EBD Group and Demy-Colton, the Alliance for Regenerative Medicine will also be hosting the RM Insight Track at the 2013 Biotech Showcase.

Strategic Planning Session

January 6, 2013

The Alliance for Regenerative Medicine holds a strategic planning session each year in San Francisco during JP Morgan Week. This year’s meeting will again be held at the California Institute for Regenerative Medicine’s (CIRM) offices and is open to the memebers of the ARM Board of Directors. Additional information on the meeting will be available in the coming weeks.

World Stem Cell Summit

December 3–5, 2012

Join ARM members and other senior delegates of the international stem cell and regenerative medicine community at the 2012 World Stem Cell Summit to discuss the most pressing issues in business, policy, science and advocacy.

Starting a Life Sciences Company

November 27, 2012

In this workshop, a leading venture investor will talk about the art of starting and building a life sciences company.

Winning Concepts That Attract Life Sciences Investments

November 14, 2012

As the funding landscape shifts, so do the investible concepts for life sciences ventures.